Inflammatory Stress Induces Statin Resistance by Disrupting 3-Hydroxy-3-Methylglutaryl-CoA Reductase Feedback Regulation
OBJECTIVE—The risk of cardiovascular disease is increased by up to 33 to 50× in chronic inflammatory states and convention doses of statins may not provide the same cardiovascular protection as in noninflamed patients. This study investigated whether the increase in 3-hydroxy-3-methylglutaryl-CoA re...
Saved in:
Published in | Arteriosclerosis, thrombosis, and vascular biology Vol. 34; no. 2; pp. 365 - 376 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Heart Association, Inc
01.02.2014
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | OBJECTIVE—The risk of cardiovascular disease is increased by up to 33 to 50× in chronic inflammatory states and convention doses of statins may not provide the same cardiovascular protection as in noninflamed patients. This study investigated whether the increase in 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCoA-R)–mediated cholesterol synthesis observed under inflammatory stress was resistant to the action of statins and if so, whether this was because of interference with the sterol regulatory element binding protein cleavage–activating protein pathway.
APPROACH AND RESULTS—Inflammatory stress was induced by adding cytokines (interleukin-1β, tumor necrosis factor-α, and interleukin-6) and lipopolysaccharides to vascular smooth muscle cells in vitro and by subcutaneous casein injection in apolipoprotein E/scavenger receptors class A/CD36 triple knockout mice in vivo. Inflammatory stress exacerbated cholesterol ester accumulation and was accompanied in vitro and in vivo by increased HMGCoA-R mRNA and protein expression mediated via activation of the sterol regulatory element binding protein cleavage–activating protein/sterol regulatory element binding protein-2 pathway. Atorvastatin reduced HMGCoA-R enzymatic activity and intracellular cholesterol synthesis in vitro. However, inflammatory stress weakened these suppressive effects. Atorvastatin at concentrations of 16 μmol/L inhibited HMGCoA-R activity by 50% in vascular smooth muscle cells, but the same concentration resulted in only 30% of HMGCoA-R activity in vascular smooth muscle cells in the presence of interleukin-1β. Knocking down sterol regulatory element binding protein cleavage–activating protein prevented statin resistance induced by interleukin-1β, and overexpression of sterol regulatory element binding protein cleavage–activating protein induced statin resistance even without inflammatory stress. In vivo, the amount of atorvastatin required to lower serum cholesterol and decrease aortic lipid accumulation rose from 2 to 10 mg/kg per day in the presence of inflammatory stress.
CONCLUSIONS—Increased cholesterol synthesis mediated by HMGCoA-R under inflammatory stress may be one of the mechanisms for intracellular lipid accumulation and statin resistance. |
---|---|
AbstractList | The risk of cardiovascular disease is increased by up to 33 to 50× in chronic inflammatory states and convention doses of statins may not provide the same cardiovascular protection as in noninflamed patients. This study investigated whether the increase in 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCoA-R)-mediated cholesterol synthesis observed under inflammatory stress was resistant to the action of statins and if so, whether this was because of interference with the sterol regulatory element binding protein cleavage-activating protein pathway.
Inflammatory stress was induced by adding cytokines (interleukin-1β, tumor necrosis factor-α, and interleukin-6) and lipopolysaccharides to vascular smooth muscle cells in vitro and by subcutaneous casein injection in apolipoprotein E/scavenger receptors class A/CD36 triple knockout mice in vivo. Inflammatory stress exacerbated cholesterol ester accumulation and was accompanied in vitro and in vivo by increased HMGCoA-R mRNA and protein expression mediated via activation of the sterol regulatory element binding protein cleavage-activating protein/sterol regulatory element binding protein-2 pathway. Atorvastatin reduced HMGCoA-R enzymatic activity and intracellular cholesterol synthesis in vitro. However, inflammatory stress weakened these suppressive effects. Atorvastatin at concentrations of 16 μmol/L inhibited HMGCoA-R activity by 50% in vascular smooth muscle cells, but the same concentration resulted in only 30% of HMGCoA-R activity in vascular smooth muscle cells in the presence of interleukin-1β. Knocking down sterol regulatory element binding protein cleavage-activating protein prevented statin resistance induced by interleukin-1β, and overexpression of sterol regulatory element binding protein cleavage-activating protein induced statin resistance even without inflammatory stress. In vivo, the amount of atorvastatin required to lower serum cholesterol and decrease aortic lipid accumulation rose from 2 to 10 mg/kg per day in the presence of inflammatory stress.
Increased cholesterol synthesis mediated by HMGCoA-R under inflammatory stress may be one of the mechanisms for intracellular lipid accumulation and statin resistance. Objective— The risk of cardiovascular disease is increased by up to 33 to 50× in chronic inflammatory states and convention doses of statins may not provide the same cardiovascular protection as in noninflamed patients. This study investigated whether the increase in 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCoA-R)–mediated cholesterol synthesis observed under inflammatory stress was resistant to the action of statins and if so, whether this was because of interference with the sterol regulatory element binding protein cleavage–activating protein pathway. Approach and Results— Inflammatory stress was induced by adding cytokines (interleukin-1β, tumor necrosis factor-α, and interleukin-6) and lipopolysaccharides to vascular smooth muscle cells in vitro and by subcutaneous casein injection in apolipoprotein E/scavenger receptors class A/CD36 triple knockout mice in vivo. Inflammatory stress exacerbated cholesterol ester accumulation and was accompanied in vitro and in vivo by increased HMGCoA-R mRNA and protein expression mediated via activation of the sterol regulatory element binding protein cleavage–activating protein/sterol regulatory element binding protein-2 pathway. Atorvastatin reduced HMGCoA-R enzymatic activity and intracellular cholesterol synthesis in vitro. However, inflammatory stress weakened these suppressive effects. Atorvastatin at concentrations of 16 μmol/L inhibited HMGCoA-R activity by 50% in vascular smooth muscle cells, but the same concentration resulted in only 30% of HMGCoA-R activity in vascular smooth muscle cells in the presence of interleukin-1β. Knocking down sterol regulatory element binding protein cleavage–activating protein prevented statin resistance induced by interleukin-1β, and overexpression of sterol regulatory element binding protein cleavage–activating protein induced statin resistance even without inflammatory stress. In vivo, the amount of atorvastatin required to lower serum cholesterol and decrease aortic lipid accumulation rose from 2 to 10 mg/kg per day in the presence of inflammatory stress. Conclusions— Increased cholesterol synthesis mediated by HMGCoA-R under inflammatory stress may be one of the mechanisms for intracellular lipid accumulation and statin resistance. OBJECTIVE—The risk of cardiovascular disease is increased by up to 33 to 50× in chronic inflammatory states and convention doses of statins may not provide the same cardiovascular protection as in noninflamed patients. This study investigated whether the increase in 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCoA-R)–mediated cholesterol synthesis observed under inflammatory stress was resistant to the action of statins and if so, whether this was because of interference with the sterol regulatory element binding protein cleavage–activating protein pathway. APPROACH AND RESULTS—Inflammatory stress was induced by adding cytokines (interleukin-1β, tumor necrosis factor-α, and interleukin-6) and lipopolysaccharides to vascular smooth muscle cells in vitro and by subcutaneous casein injection in apolipoprotein E/scavenger receptors class A/CD36 triple knockout mice in vivo. Inflammatory stress exacerbated cholesterol ester accumulation and was accompanied in vitro and in vivo by increased HMGCoA-R mRNA and protein expression mediated via activation of the sterol regulatory element binding protein cleavage–activating protein/sterol regulatory element binding protein-2 pathway. Atorvastatin reduced HMGCoA-R enzymatic activity and intracellular cholesterol synthesis in vitro. However, inflammatory stress weakened these suppressive effects. Atorvastatin at concentrations of 16 μmol/L inhibited HMGCoA-R activity by 50% in vascular smooth muscle cells, but the same concentration resulted in only 30% of HMGCoA-R activity in vascular smooth muscle cells in the presence of interleukin-1β. Knocking down sterol regulatory element binding protein cleavage–activating protein prevented statin resistance induced by interleukin-1β, and overexpression of sterol regulatory element binding protein cleavage–activating protein induced statin resistance even without inflammatory stress. In vivo, the amount of atorvastatin required to lower serum cholesterol and decrease aortic lipid accumulation rose from 2 to 10 mg/kg per day in the presence of inflammatory stress. CONCLUSIONS—Increased cholesterol synthesis mediated by HMGCoA-R under inflammatory stress may be one of the mechanisms for intracellular lipid accumulation and statin resistance. OBJECTIVEThe risk of cardiovascular disease is increased by up to 33 to 50× in chronic inflammatory states and convention doses of statins may not provide the same cardiovascular protection as in noninflamed patients. This study investigated whether the increase in 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCoA-R)-mediated cholesterol synthesis observed under inflammatory stress was resistant to the action of statins and if so, whether this was because of interference with the sterol regulatory element binding protein cleavage-activating protein pathway.APPROACH AND RESULTSInflammatory stress was induced by adding cytokines (interleukin-1β, tumor necrosis factor-α, and interleukin-6) and lipopolysaccharides to vascular smooth muscle cells in vitro and by subcutaneous casein injection in apolipoprotein E/scavenger receptors class A/CD36 triple knockout mice in vivo. Inflammatory stress exacerbated cholesterol ester accumulation and was accompanied in vitro and in vivo by increased HMGCoA-R mRNA and protein expression mediated via activation of the sterol regulatory element binding protein cleavage-activating protein/sterol regulatory element binding protein-2 pathway. Atorvastatin reduced HMGCoA-R enzymatic activity and intracellular cholesterol synthesis in vitro. However, inflammatory stress weakened these suppressive effects. Atorvastatin at concentrations of 16 μmol/L inhibited HMGCoA-R activity by 50% in vascular smooth muscle cells, but the same concentration resulted in only 30% of HMGCoA-R activity in vascular smooth muscle cells in the presence of interleukin-1β. Knocking down sterol regulatory element binding protein cleavage-activating protein prevented statin resistance induced by interleukin-1β, and overexpression of sterol regulatory element binding protein cleavage-activating protein induced statin resistance even without inflammatory stress. In vivo, the amount of atorvastatin required to lower serum cholesterol and decrease aortic lipid accumulation rose from 2 to 10 mg/kg per day in the presence of inflammatory stress.CONCLUSIONSIncreased cholesterol synthesis mediated by HMGCoA-R under inflammatory stress may be one of the mechanisms for intracellular lipid accumulation and statin resistance. |
Author | Chen, Yaxi Moorhead, John F Li, Qing Varghese, Zac Wheeler, David C Ruan, Xiong Z Powis, Stephen H Li, Lung-Chih Ku, Halcyon Zhao, Lei Huang, Ailong |
AuthorAffiliation | From the Key Laboratory of Metabolism on Lipid and Glucose, Centre for Lipid Research, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China (Y.C., L.Z., Q.L., A.H., X.Z.R.); Division of Nephrology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan (L.C.L.); and John Moorhead Research Laboratory, Centre for Nephrology, University College London (UCL) Medical School, United Kingdom (H.K., D.C.W., Z.V., J.F.M., S.H.P., X.Z.R.) |
AuthorAffiliation_xml | – name: From the Key Laboratory of Metabolism on Lipid and Glucose, Centre for Lipid Research, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China (Y.C., L.Z., Q.L., A.H., X.Z.R.); Division of Nephrology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan (L.C.L.); and John Moorhead Research Laboratory, Centre for Nephrology, University College London (UCL) Medical School, United Kingdom (H.K., D.C.W., Z.V., J.F.M., S.H.P., X.Z.R.) |
Author_xml | – sequence: 1 givenname: Yaxi surname: Chen fullname: Chen, Yaxi organization: From the Key Laboratory of Metabolism on Lipid and Glucose, Centre for Lipid Research, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China (Y.C., L.Z., Q.L., A.H., X.Z.R.); Division of Nephrology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan (L.C.L.); and John Moorhead Research Laboratory, Centre for Nephrology, University College London (UCL) Medical School, United Kingdom (H.K., D.C.W., Z.V., J.F.M., S.H.P., X.Z.R.) – sequence: 2 givenname: Halcyon surname: Ku fullname: Ku, Halcyon – sequence: 3 givenname: Lei surname: Zhao fullname: Zhao, Lei – sequence: 4 givenname: David surname: Wheeler middlename: C fullname: Wheeler, David C – sequence: 5 givenname: Lung-Chih surname: Li fullname: Li, Lung-Chih – sequence: 6 givenname: Qing surname: Li fullname: Li, Qing – sequence: 7 givenname: Zac surname: Varghese fullname: Varghese, Zac – sequence: 8 givenname: John surname: Moorhead middlename: F fullname: Moorhead, John F – sequence: 9 givenname: Stephen surname: Powis middlename: H fullname: Powis, Stephen H – sequence: 10 givenname: Ailong surname: Huang fullname: Huang, Ailong – sequence: 11 givenname: Xiong surname: Ruan middlename: Z fullname: Ruan, Xiong Z |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24233489$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kEtPwzAQhC0EolD4AxxQjlwMduy8jqE8WgmExOsaOc6mDXXiYjui-fcYpXBEWsk7q5lP8hyj_U53gNAZJZeUxvQqf32_zue5F-ySEepnDx3RKOSYxyze9ztJMhzFPJygY2s_CCE8DMkhmoQ8ZIyn2RHaLrpaibYVTpsheHEGrA0WXdVLsF4K13TBM9jGOtFJCMohuGms6Tf-vgwYng-V0dsBM_wIbjWopeqdMIPCM537nMc4YSG4A6hKIdf-tOyVh-ruBB3UQlk43b1T9HZ3-zqb44en-8Usf8AyIhnFMQcBTJC6ToCSKpM0SUqoJY2TiBBZRRGVnJTUF5JmDFImKACIqgxTiCIQbIouRu7G6M8erCvaxkpQSnSge1tQnpEkphnLvDUcrdJoaw3UxcY0rf9OQUnx03ixa9wLVoyN-9D5jt-XLVR_kd-KvSEeDV9aOTB2rfovMMUKhHKr_8jf0g-RRg |
CitedBy_id | crossref_primary_10_1038_s41598_022_14713_w crossref_primary_10_7717_peerj_15435 crossref_primary_10_1186_s12967_015_0684_9 crossref_primary_10_1016_j_numecd_2014_05_009 crossref_primary_10_1016_j_clinthera_2018_08_014 crossref_primary_10_3390_metabo12050462 crossref_primary_10_3390_ijms18010104 crossref_primary_10_1016_j_biopha_2017_11_116 crossref_primary_10_1210_en_2019_00588 crossref_primary_10_1016_j_kint_2019_09_024 crossref_primary_10_3389_fimmu_2021_796383 crossref_primary_10_3389_fendo_2024_1381746 crossref_primary_10_1007_s10529_018_2597_1 crossref_primary_10_3390_ijerph15122733 crossref_primary_10_1161_STROKEAHA_120_029680 crossref_primary_10_1016_j_kint_2021_01_016 crossref_primary_10_1111_bph_13269 crossref_primary_10_3390_ph17040498 crossref_primary_10_1016_j_jcmgh_2022_03_006 crossref_primary_10_1253_circrep_CR_21_0080 crossref_primary_10_1016_j_atherosclerosis_2015_10_110 crossref_primary_10_1016_j_ejphar_2014_07_048 crossref_primary_10_1039_D2FO03238D crossref_primary_10_1152_ajpgi_00273_2023 crossref_primary_10_1038_s41467_023_35944_z crossref_primary_10_1016_j_atherosclerosis_2015_04_817 crossref_primary_10_1016_j_kint_2021_02_022 crossref_primary_10_1186_s12944_015_0114_2 crossref_primary_10_1080_02652048_2020_1836058 crossref_primary_10_1016_j_kint_2017_09_011 crossref_primary_10_1186_s12976_015_0006_1 crossref_primary_10_1002_mnfr_201500941 crossref_primary_10_2217_fca_15_46 crossref_primary_10_1093_ndt_gfu203 crossref_primary_10_1096_fj_201800975RRR crossref_primary_10_1016_j_yexcr_2018_03_032 crossref_primary_10_1002_phar_2675 crossref_primary_10_1016_j_medcle_2016_04_058 crossref_primary_10_1038_srep39982 crossref_primary_10_1016_j_cjca_2019_10_014 crossref_primary_10_1016_j_medcli_2015_01_016 crossref_primary_10_1038_s41598_019_44885_x crossref_primary_10_1681_ASN_2017020201 crossref_primary_10_1038_srep23587 crossref_primary_10_2337_db14_1314 crossref_primary_10_1172_JCI173278 |
Cites_doi | 10.1016/S0140-6736(03)13638-0 10.1023/A:1015175108183 10.1161/01.ATV.0000217957.93135.c2 10.1152/ajpheart.00492.2009 10.1111/j.1365-2249.2011.04331.x 10.1016/S0272-6386(98)70145-3 10.1074/jbc.M407167200 10.1007/s00253-003-1553-7 10.1053/j.ajkd.2003.10.037 10.1152/ajprenal.00209.2007 10.1161/hc0902.104353 10.1016/S0092-8674(05)80095-9 10.1161/01.ATV.10.5.680 10.1056/NEJMoa0810177 10.1161/01.CIR.96.11.4095 10.1046/j.1523-1755.1999.00587.x 10.1038/nrm1174 10.1161/01.CIR.102.7.779 10.1002/hep.22423 10.1056/NEJM199901143400207 10.1073/pnas.1735526100 10.1136/bmj.316.7138.1127 10.1093/cvr/cvn071 10.1152/ajpheart.00096.2012 10.1016/S1097-2765(02)00822-5 10.1161/atvbaha.107.142570 10.1124/jpet.105.093088 10.1016/S0140-6736(82)91513-6 10.1016/j.jchromb.2005.08.008 10.1038/nrneph.2009.184 10.1016/j.atherosclerosis.2006.07.015 10.1056/NEJMoa042378 10.1152/ajprenal.00341.2010 10.1161/CIRCGENETICS.108.795013 10.1074/jbc.M209649200 10.1056/NEJMoa043545 10.1097/01.ASN.0000050414.52908.DA 10.1046/j.1523-1755.2001.00025.x |
ContentType | Journal Article |
Copyright | 2014 American Heart Association, Inc. |
Copyright_xml | – notice: 2014 American Heart Association, Inc. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1161/ATVBAHA.113.301301 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE CrossRef MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1524-4636 |
EndPage | 376 |
ExternalDocumentID | 10_1161_ATVBAHA_113_301301 24233489 10.1161/ATVBAHA.113.301301 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | - .Z2 01R 08R 0R 1J1 23N 2WC 3O- 40H 4Q1 4Q2 4Q3 53G 55 5GY 5RE 5VS 71W 77Y 7O 7O~ AAAXR AAMOA AAMTA AAPBV AARTV AAXQO ABBUW ABXVJ ABZAD ACDDN ACEWG ACGFS ACGOD ACPRK ACWDW ACWRI ACXNZ ADACO ADBBV ADFPA ADNKB AE3 AENEX AFFNX AFUWQ AHMBA AHULI AHVBC AIJEX AJIOK AJNYG AJYGW ALMA_UNASSIGNED_HOLDINGS AMJPA ASCII AWKKM BAWUL BOYCO C1A C45 CS3 DIK DUNZO E.X E3Z EBS EJD EX3 F2K F2L F2M F2N F5P FL- FRP FW0 GJ GX1 H0 H0~ H13 HZ IKYAY IN IN~ J5H JF9 JG8 JK3 JK8 K8S KD2 KMI KQ8 L-C L7B LI0 N9A N~7 N~B N~M O0- O9- OAG OAH OB2 OCUKA ODA OHASI OK1 OL1 OLG OLH OLU OLV OLW OLY OLZ OPUJH ORVUJ OUVQU OVD OVDNE OVIDH OVLEI OWW OWY OXXIT P-K P2P PQEST PQQKQ PZZ RAH RHF RIG RLZ RSW S4R S4S V2I WOQ WOW X3V X3W X7M Z2 ZA5 ZGI --- .3C .55 .GJ 0R~ AAAAV AAGIX AAHPQ AAIQE AAQKA AASCR AASOK ABASU ABDIG ABJNI ABQRW ABVCZ ACCJW ACILI ACLDA ACXJB ADGGA ADHPY AE6 AEETU AFDTB AGINI AHJKT AHOMT AHQNM AHRYX AINUH AJNWD AJZMW AKULP ALMTX AMKUR AMNEI AOHHW AYCSE BQLVK BS7 CGR CUY CVF DIWNM ECM EEVPB EIF ERAAH FCALG GNXGY GQDEL HLJTE HZ~ IKREB IPNFZ NPM OWU OWV OWX OWZ T8P TEORI TR2 TSPGW VVN W3M W8F XXN XYM YFH ZZMQN AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c5091-64eae3a0ff7e10d9c177befc167500cd551c40b1116893e83a1eeeadb28e55ea3 |
ISSN | 1079-5642 |
IngestDate | Fri Oct 25 01:05:45 EDT 2024 Fri Aug 23 01:18:58 EDT 2024 Tue Oct 15 23:47:42 EDT 2024 Thu Aug 13 19:47:33 EDT 2020 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | cholesterol drug resistance inflammation statins |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c5091-64eae3a0ff7e10d9c177befc167500cd551c40b1116893e83a1eeeadb28e55ea3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.ahajournals.org/doi/pdf/10.1161/ATVBAHA.113.301301 |
PMID | 24233489 |
PQID | 1490761939 |
PQPubID | 23479 |
PageCount | 12 |
ParticipantIDs | proquest_miscellaneous_1490761939 crossref_primary_10_1161_ATVBAHA_113_301301 pubmed_primary_24233489 wolterskluwer_health_10_1161_ATVBAHA_113_301301 |
ProviderPackageCode | L-C C45 7O~ AARTV ADFPA OLH ASCII OLG AAMOA ODA ABZAD ABBUW JK3 ADNKB JK8 H0~ 1J1 OLV OLU JG8 OLW OLZ OLY F2K F2M F2L F2N OHASI AHVBC AJNYG FL- KMI K8S OVLEI AJIOK OPUJH V2I S4R S4S 4Q1 DUNZO OAG 4Q2 OVDNE 4Q3 AMJPA OAH OVD 71W AHULI OB2 ACEWG .Z2 N~7 IKYAY OVIDH AWKKM 40H N~B OUVQU ORVUJ X3V X3W ACDDN ACWRI BOYCO AIJEX AAXQO AAMTA AAAXR E.X OWW OCUKA OWY 01R ACXNZ OL1 ABXVJ IN~ KD2 OXXIT 77Y ACWDW JF9 FW0 |
PublicationCentury | 2000 |
PublicationDate | 2014-February 2014-Feb 2014-02-00 20140201 |
PublicationDateYYYYMMDD | 2014-02-01 |
PublicationDate_xml | – month: 02 year: 2014 text: 2014-February |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Arteriosclerosis, thrombosis, and vascular biology |
PublicationTitleAlternate | Arterioscler Thromb Vasc Biol |
PublicationYear | 2014 |
Publisher | American Heart Association, Inc |
Publisher_xml | – name: American Heart Association, Inc |
References | e_1_3_5_28_2 e_1_3_5_27_2 e_1_3_5_25_2 e_1_3_5_24_2 e_1_3_5_23_2 e_1_3_5_22_2 e_1_3_5_21_2 e_1_3_5_29_2 e_1_3_5_2_2 Black AE (e_1_3_5_26_2) 1998; 26 e_1_3_5_40_2 e_1_3_5_41_2 e_1_3_5_8_2 e_1_3_5_20_2 e_1_3_5_7_2 Baltz ML (e_1_3_5_38_2) 1980; 39 e_1_3_5_9_2 e_1_3_5_4_2 e_1_3_5_3_2 e_1_3_5_6_2 e_1_3_5_5_2 e_1_3_5_17_2 e_1_3_5_39_2 e_1_3_5_16_2 e_1_3_5_15_2 e_1_3_5_37_2 e_1_3_5_14_2 e_1_3_5_36_2 e_1_3_5_12_2 e_1_3_5_35_2 e_1_3_5_13_2 e_1_3_5_34_2 e_1_3_5_10_2 e_1_3_5_33_2 e_1_3_5_11_2 e_1_3_5_32_2 e_1_3_5_19_2 e_1_3_5_18_2 e_1_3_5_31_2 e_1_3_5_30_2 |
References_xml | – ident: e_1_3_5_7_2 doi: 10.1016/S0140-6736(03)13638-0 – ident: e_1_3_5_31_2 doi: 10.1023/A:1015175108183 – ident: e_1_3_5_9_2 doi: 10.1161/01.ATV.0000217957.93135.c2 – ident: e_1_3_5_32_2 doi: 10.1152/ajpheart.00492.2009 – ident: e_1_3_5_30_2 doi: 10.1111/j.1365-2249.2011.04331.x – ident: e_1_3_5_41_2 doi: 10.1016/S0272-6386(98)70145-3 – ident: e_1_3_5_36_2 doi: 10.1074/jbc.M407167200 – ident: e_1_3_5_24_2 doi: 10.1007/s00253-003-1553-7 – ident: e_1_3_5_4_2 doi: 10.1053/j.ajkd.2003.10.037 – ident: e_1_3_5_39_2 doi: 10.1152/ajprenal.00209.2007 – ident: e_1_3_5_16_2 doi: 10.1161/hc0902.104353 – ident: e_1_3_5_13_2 doi: 10.1016/S0092-8674(05)80095-9 – ident: e_1_3_5_21_2 doi: 10.1161/01.ATV.10.5.680 – ident: e_1_3_5_6_2 doi: 10.1056/NEJMoa0810177 – ident: e_1_3_5_18_2 doi: 10.1161/01.CIR.96.11.4095 – ident: e_1_3_5_23_2 doi: 10.1046/j.1523-1755.1999.00587.x – ident: e_1_3_5_14_2 doi: 10.1038/nrm1174 – ident: e_1_3_5_17_2 doi: 10.1161/01.CIR.102.7.779 – volume: 26 start-page: 755 year: 1998 ident: e_1_3_5_26_2 article-title: Metabolism and excretion studies in mouse after single and multiple oral doses of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. publication-title: Drug Metab Dispos contributor: fullname: Black AE – ident: e_1_3_5_37_2 doi: 10.1002/hep.22423 – ident: e_1_3_5_15_2 doi: 10.1056/NEJM199901143400207 – ident: e_1_3_5_20_2 doi: 10.1073/pnas.1735526100 – ident: e_1_3_5_11_2 doi: 10.1136/bmj.316.7138.1127 – volume: 39 start-page: 355 year: 1980 ident: e_1_3_5_38_2 article-title: Differences in the acute phase responses of serum amyloid P-component (SAP) and C3 to injections of casein or bovine serum albumin in amyloid-susceptible and -resistant mouse strains. publication-title: Clin Exp Immunol contributor: fullname: Baltz ML – ident: e_1_3_5_29_2 doi: 10.1093/cvr/cvn071 – ident: e_1_3_5_33_2 doi: 10.1152/ajpheart.00096.2012 – ident: e_1_3_5_12_2 doi: 10.1016/S1097-2765(02)00822-5 – ident: e_1_3_5_27_2 doi: 10.1161/atvbaha.107.142570 – ident: e_1_3_5_28_2 doi: 10.1124/jpet.105.093088 – ident: e_1_3_5_19_2 doi: 10.1016/S0140-6736(82)91513-6 – ident: e_1_3_5_25_2 doi: 10.1016/j.jchromb.2005.08.008 – ident: e_1_3_5_8_2 doi: 10.1038/nrneph.2009.184 – ident: e_1_3_5_35_2 doi: 10.1016/j.atherosclerosis.2006.07.015 – ident: e_1_3_5_3_2 doi: 10.1056/NEJMoa042378 – ident: e_1_3_5_40_2 doi: 10.1152/ajprenal.00341.2010 – ident: e_1_3_5_2_2 doi: 10.1161/CIRCGENETICS.108.795013 – ident: e_1_3_5_34_2 doi: 10.1074/jbc.M209649200 – ident: e_1_3_5_5_2 doi: 10.1056/NEJMoa043545 – ident: e_1_3_5_10_2 doi: 10.1097/01.ASN.0000050414.52908.DA – ident: e_1_3_5_22_2 doi: 10.1046/j.1523-1755.2001.00025.x |
SSID | ssj0004220 |
Score | 2.3896976 |
Snippet | OBJECTIVE—The risk of cardiovascular disease is increased by up to 33 to 50× in chronic inflammatory states and convention doses of statins may not provide the... The risk of cardiovascular disease is increased by up to 33 to 50× in chronic inflammatory states and convention doses of statins may not provide the same... Objective— The risk of cardiovascular disease is increased by up to 33 to 50× in chronic inflammatory states and convention doses of statins may not provide... OBJECTIVEThe risk of cardiovascular disease is increased by up to 33 to 50× in chronic inflammatory states and convention doses of statins may not provide the... |
SourceID | proquest crossref pubmed wolterskluwer |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 365 |
SubjectTerms | Animals Apolipoproteins E - deficiency Apolipoproteins E - genetics Atorvastatin Calcium CD36 Antigens - deficiency CD36 Antigens - genetics Cholesterol - blood Cholesterol, Dietary Cytokines - metabolism Disease Models, Animal Dose-Response Relationship, Drug Drug Resistance Feedback, Physiological Hep G2 Cells Heptanoic Acids - pharmacology Humans Hydroxymethylglutaryl CoA Reductases - metabolism Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology Hyperlipidemias - blood Hyperlipidemias - drug therapy Hyperlipidemias - enzymology Hyperlipidemias - genetics Inflammation - blood Inflammation - enzymology Inflammation Mediators - metabolism Intracellular Signaling Peptides and Proteins - genetics Intracellular Signaling Peptides and Proteins - metabolism Male Membrane Proteins - genetics Membrane Proteins - metabolism Mice Mice, Inbred C57BL Mice, Knockout Muscle, Smooth, Vascular - drug effects Muscle, Smooth, Vascular - enzymology Myocytes, Smooth Muscle - drug effects Myocytes, Smooth Muscle - enzymology Pyrroles - pharmacology RNA Interference Scavenger Receptors, Class A - deficiency Scavenger Receptors, Class A - genetics Stress, Physiological Time Factors Transfection |
Title | Inflammatory Stress Induces Statin Resistance by Disrupting 3-Hydroxy-3-Methylglutaryl-CoA Reductase Feedback Regulation |
URI | https://www.ncbi.nlm.nih.gov/pubmed/24233489 https://search.proquest.com/docview/1490761939 |
Volume | 34 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKkBAIIe6Um4zE2-QtiXN9DBOoXIaE1KHBS-Q4zhatbaqmEQv_g__LObHTZBQm4CVq3NaJcr6ci_2dcwh5afEcfDYvYxE4s8wNhc-iKHdZoDIpbKHAiGOi8OFHf3Lkvjv2jkejHwPWUr1O9-T33-aV_I9UYQzkilmy_yDZzaQwAJ9BvnAECcPxr2T8dpGDQOd6o9xkfUCMXSPLCjOF2lyVCj1EfH3B0cyKalUvW6YzZ6dNhhwWxhm2kW5mJ3CrYtXM2EEZw_-wECyYuN0c7Fsq5BkMnZheX0OPNkZOaFFWcGtgcHXFAuy9ME-7M1ya3xBeTdGnnlWg1d4XcV70u0qtPRQz2fQcga-nol3U_aCKgR1RJo-xZeabBV-zhGG7HesZLZBRu47LsHTZUC-bRc5iEB5rJct1d4lt5e-j8o-nn1_Fkxib1exx3Je1hz8GAS7nLRzQkeSu7l_0S8nt7qsr5KoTRB4yRd9_GhShdxyry7_y7f3tC2KFaTPFRXdnK4a5QW5-K5EWUZ21WRED32Z6m9wyQQmNNcLukJFa3CXXDg3t4h45HwKNaqBRAzSqgUZ7oNG0oT3Q6OVAoxug0Q5otAfafXL05vX0YMJMyw4m0fNkvquE4sLK80DZVhZJOwhSlUsb4lLLkhn459K1UjCwPjjKKuTCVgqUWeqEyvOU4A_IzqJcqEeECieNpO-GMg8z18khVAiw-KET2tyPvMgZk93uySZLXZklaSNa306MSOCEJ1okY_Kie_gJKFDcFRMLVdYVxL5Ru5bHozF5qKWyma-T4pjsXxBTopOUL7ne4z_O9YRc79-Bp2RnvarVM3Bs1-nzFmY_AT0upeQ |
link.rule.ids | 315,786,790,27955,27956 |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Inflammatory+stress+induces+statin+resistance+by+disrupting+3-hydroxy-3-methylglutaryl-CoA+reductase+feedback+regulation&rft.jtitle=Arteriosclerosis%2C+thrombosis%2C+and+vascular+biology&rft.au=Chen%2C+Yaxi&rft.au=Ku%2C+Halcyon&rft.au=Zhao%2C+Lei&rft.au=Wheeler%2C+David+C&rft.date=2014-02-01&rft.eissn=1524-4636&rft.volume=34&rft.issue=2&rft.spage=365&rft_id=info:doi/10.1161%2FATVBAHA.113.301301&rft_id=info%3Apmid%2F24233489&rft.externalDocID=24233489 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1079-5642&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1079-5642&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1079-5642&client=summon |